Tiny Health Raises $33M for Microbiome Intelligence

Tiny Health began by making the microbiome legible for parents who had little more than symptoms and guesswork. Its $33 million Series B arrives at a more demanding stage: the company now has to make a growing body of biological data useful to consumers, practitioners, health partners, and researchers without making the science sound more settled than it is.

The San Francisco company announced the financing on September 29, 2026. B Capital led the round, with participation from new investors Black Opal Ventures, Denver Ventures, Pave Health Ventures, Alumni Ventures, Gaingels, and Pari Passu Ventures. Returning backers Spero Ventures, TheVentureCity, and Overwater Ventures also participated. Tiny Health says the round brings its total funding to $46 million.

What Happened

Tiny Health will use the new capital to expand its microbiome testing platform, develop its data and artificial intelligence capabilities, and support a $5 million research program. The company is also introducing TinyAI, which it says was trained on nearly 200,000 proprietary microbiome profiles, along with Gut Microbiome Age and Gut Resilience metrics designed to make longitudinal results easier to interpret.

Those products sit inside a business that has widened substantially since its launch. Founder and CEO Cheryl Sew Hoy started Tiny Health after searching for better answers about her daughter's eczema and food sensitivities. The company's first tests focused on mothers and babies. It now offers gut and vaginal microbiome testing across life stages and sells infrastructure to practitioners, wellness brands, and research partners through Powered by Tiny.

Tiny Health says it has served nearly 200,000 customers and more than 6,000 practitioners. Beauty Independent reported that annual revenue has reached eight figures and is at least doubling each year, with the business-to-business operation accounting for roughly half of revenue. The publication also reported that adult test volume has surpassed pediatric testing and that Powered by Tiny grew fourfold over the past year. These are company-reported operating metrics rather than independently audited results.

From an Infant Test to a Data Platform

The strategic shift is larger than an expansion of the test menu. Tiny Health is trying to turn consumer testing, practitioner distribution, enterprise partnerships, and research into a reinforcing system. More tests can create a broader dataset. A broader dataset can support better comparisons and research questions. Stronger evidence can make the resulting reports more useful to practitioners and health partners.

That sequence is not automatic. Microbiome profiles are complex, and detecting a pattern is different from showing that a particular intervention caused a health outcome. Consumers can receive a highly detailed report while still facing uncertainty about what to do next. Tiny Health acknowledges that boundary: its tests are not diagnostic and do not replace medical care.

The company's leadership additions reflect the broader ambition. Pediatrician Elisa Song joined as chief medical officer in 2025, and physician and investor Taylor Sittler joined as chief business officer. Donald Koo serves as chief technology officer, while Kimberley Sukhum leads research and development. The organization now has to translate technical depth into evidence that clinicians can evaluate and advice that remains proportionate to what the data supports.

Why the Research Program Matters

Tiny Health points to a 2025 randomized controlled trial as early evidence that microbiome-guided care may improve outcomes. The open-label study followed 54 C-section-born infants, with 25 in the intervention group and 29 in the control group. It reported lower odds of atopic dermatitis in the intervention group.

The finding is promising but preliminary. The study was small, had a short follow-up period, used parent-reported outcomes, and was sponsored by Tiny Health. Several authors were employees or affiliates of the company. Those limitations do not erase the result, but they make replication and larger independent studies important.

The new $5 million research commitment is therefore central to the financing story. Tiny Health is not only funding distribution and product development. It is investing in the evidence needed to decide which microbiome signals are clinically meaningful, which interventions are worth testing, and where consumer guidance should stop.

That distinction matters across the category. An Associated Press review noted that microbiome science is still evolving and cautioned consumers against making major treatment decisions based only on commercial test results. Tiny Health's opportunity is to make its dataset useful without presenting correlation as clinical certainty.

What the Round Signals

B Capital is backing a company that has moved beyond a single consumer product. Tiny Health now combines direct-to-consumer testing, practitioner distribution, white-label infrastructure, research partnerships, and a proprietary dataset. If those components reinforce one another, the company can become more valuable as both a testing provider and an evidence platform.

The risk is that the visible sophistication of a report advances faster than the evidence behind the recommended action. AI can help organize profiles, identify patterns, and personalize explanations. It cannot by itself establish that an intervention works or that a result should change medical care.

For Tiny Health, the next phase will be measured by more than test volume or model size. The harder benchmark is whether its platform can produce findings that clinicians can defend, researchers can reproduce, and families can use without confusing precision with certainty. The Series B gives the company more capital to close that gap. The $5 million research allocation makes the gap part of the operating plan rather than a footnote.